muc1/cll1/cd33/cd38/cd56/cd123-specific gene-engineered t cells
Cell therapyexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 15, 2017 (NCT03222674)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Neural cell adhesion molecule 1Immunity, passive
NCAM1 immunity, passive
- ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1Immunity, passive
CD38 immunity, passive
- Myeloid cell surface antigen CD33Immunity, passive
CD33 immunity, passive
- Mucin-1Immunity, passive
MUC1 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03222674 | Phase 1/Phase 2 (Phase 2) | Jul 15, 2017 | Shenzhen Geno-Immune Medical Institute, Southern Medical University, The First People's Hospital of Yunan Province |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Shenzhen Geno-Immune Medical Institute | Academic/Hospital | 1 | 1 | 1 | 2017 |
| Southern Medical University | Academic/Hospital | 1 | 0 | 1 | 2017 |
| The First People's Hospital of Yunan Province | Academic/Hospital | 1 | 0 | 1 | 2017 |
3 organizations
Page 1 / 1